Premium
A multicenter observational study of the real‐world use of docetaxel for metastatic castration‐resistant prostate cancer in China
Author(s) -
He Dalin,
Sun Zhongquan,
Guo Jianming,
Zhang Zhigen,
Shan Yuxi,
Ma Lulin,
Li Hanzhong,
Jin Jie,
Huang Yiran,
Xiao Jiaquan,
Wei Qiang,
Ye Dingwei
Publication year - 2019
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.13142
Subject(s) - docetaxel , medicine , prostate cancer , oncology , estramustine , adverse effect , hormonal therapy , prostate specific antigen , metastasis , observational study , cancer , urology , prostate disease
Aim To investigate the use of docetaxel for the treatment of metastatic castration‐resistant prostate cancer (mCRPC) in real‐world clinical practice in China. Methods This single‐arm, prospective, observational study was conducted at 32 study centers in China and included male patients aged ≥18 years with histologically confirmed prostate cancer who received ≥1 dose of docetaxel following failure of hormonal therapy (disease progression with serum testosterone <50 ng/dL). The primary aim was to investigate patterns of docetaxel treatment. Results Overall 403 patients were included between August 2011 and June 2016; patients initiated docetaxel after failure of first‐ (42.2% [170]), second‐ (31.0% [125]) and ≥third‐line (12.7% [51]) hormonal therapy, estramustine (11.4% [46]) or other (2.7% [11]). The planned cycles of docetaxel therapy were completed by 30.8% of patients, and the mean (SD) number of cycles received was 4.4 (2.86). Median overall survival (mOS) was 22.4 (95% CI, 20.4–25.8) months and the prostate‐specific antigen (PSA) response rate in patients with available data was 70.9% (168/237), with no differences in mOS and PSA response rates between treatment settings. Subgroup analysis revealed higher mOS in patients without visceral metastasis versus those with such metastases (22.9 vs. 17.4 months; P = 0.022). No new safety signals were observed and the most common adverse events associated with docetaxel were granulocytopenia (5%) and leukopenia (4.5%). Conclusion Data from this study showed that around three‐quarters of Chinese patients with mCRPC treated with docetaxel initiated treatment following first‐ or second‐line hormonal therapy and no new safety signals were observed.